Registered Kenya · PPB

GALAXY'S TRELAZ 50

TRELAGLIPTIN

H2021/CTD8372/18156 50MG GENERIC/BIOSIMILARS

What it does

Trelagliptin is a medication used to help control blood sugar levels in people with type 2 diabetes.

Commonly used for: type 2 diabetes, diabetes mellitus

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
H2021/CTD8372/18156
Registration date
2021-08-27 00:00:00
Expiry date
2026 August 27
Status
Registered
Active ingredient
TRELAGLIPTIN
Dosage form
50MG
Strength
-
Pack size
1 X 4 TABLETS
Therapeutic class
GENERIC/BIOSIMILARS
Manufacturer / MAH
Galaxy Pharmaceutical
Applicant / LTR
GALAXY PHARMACEUTICALS LTD
Country of origin
FOREIGN
Manufacturer location
PRQC+GJ5, 3rd Parklands Ave, Nairobi, Kenya

Source: Pharmacy and Poisons Board · fetched 2026-01-28 19:56:10 · updated 2026-08-07 02:28:56

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About this medicine

Trelagliptin is a medication used to help control blood sugar levels in people with type 2 diabetes.

What it treats

  • type 2 diabetes
  • diabetes mellitus

How it works

Trelagliptin works by increasing the levels of insulin produced by the body after meals and decreasing the amount of sugar produced by the liver.

Who it's for

This medication is for adults with type 2 diabetes who need help managing their blood sugar levels.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: trelagliptin

BNF-referenced

Trelagliptin is a novel, long-acting DPP-4 inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting the enzyme DPP-4, trelagliptin increases the levels of incretin hormones, which promote insulin secretion and decrease glucagon levels in response to meals, thereby aiding in glycemic control.

Indications

  • Type 2 diabetes mellitus

Dosage

Children: Refer to BNF for Children for specific dosing guidelines.

Adults: Refer to BNF for specific dosing guidelines.

Mechanism of action

Trelagliptin selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for degrading incretin hormones such as GLP-1 and GIP. By prolonging the action of these hormones, trelagliptin enhances insulin secretion from pancreatic beta cells and suppresses glucagon secretion from alpha cells, leading to improved glucose homeostasis.

Pharmacodynamics

The pharmacodynamic effects of trelagliptin include increased insulin secretion in a glucose-dependent manner, reduced glucagon release, and improved glycemic control. The long duration of action allows for once-weekly dosing, providing sustained pharmacological effects.

Pharmacokinetics

Trelagliptin exhibits linear pharmacokinetics with a terminal half-life of approximately 24-30 hours. After subcutaneous administration, peak plasma concentrations are reached within 24 hours. The drug is primarily eliminated via the kidneys, with a small proportion undergoing hepatic metabolism. The systemic bioavailability is high, allowing for effective oral dosing.

Contra-indications

  • Hypersensitivity to trelagliptin or any of its components
  • Type 1 diabetes mellitus
  • Diabetic ketoacidosis

Adverse effects

  • Headache
  • Nausea
  • Diarrhea
  • Hypoglycemia
  • Upper respiratory tract infection
  • Pancreatitis
  • Allergic reactions

Interactions

  • May enhance the hypoglycemic effect of other antidiabetic agents
  • No significant drug interactions reported with common medications

Precautions

  • Use with caution in patients with renal impairment
  • Monitor for signs of pancreatitis
  • Consider the risk of hypoglycemia when used with other antidiabetic medications

Pregnancy

There is insufficient data on the use of trelagliptin in pregnancy. It should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether trelagliptin is excreted in human milk. Caution should be exercised when trelagliptin is administered to a nursing woman.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

  • Tablets
PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: trelagliptin

PubChem CID 15983988

Molecular formula: C18H20FN5O2

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.